Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: Open-End Fund
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: Global

Danske Invest-Bioteknologi Fund

+ Add to Watchlist

DANIBIO:DC

348.4000 DKK 1.1000 0.32%

As of 11:00:00 ET on 03/31/2015.

Snapshot for Danske Invest-Bioteknologi Fund (DANIBIO)

Open: 349.8000 High - Low: 352.3000 - 347.8000 Primary Exchange: Copenhagen
Volume: 34,280 52-Week Range: 164.1000 - 372.7000 Beta vs BTK: 0.9697

ETF Chart for DANIBIO

No chart data available.
  • DANIBIO:DC 348.4000
  • 1D
  • 1M
  • 1Y
347.3000
Interactive DANIBIO Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for DANIBIO

Danske Invest Bioteknologi Fund is an open-end fund registered in Denmark. The Fund's objective is capital appreciation, and to outperform NASDAQ's biotech-index(NBI). The Fund invests worldwide in equity of biotechnology companies, and companies closely related to the biotechnology sector.

Inception Date: 2000-05-26 Telephone: 45-3333-7171
Managers: -
Web Site: www.danskeinvest.dk

Fundamentals for DANIBIO

NAV (on 2015-03-31) 344.8400
Assets (M) (on 2015-02-27) 1,302.8540
Shares out (M) 0.00
Market Cap (M) 0.00
% Premium 1.03
Average 52-Week % Premium 0.9466
Fund Leveraged N

Dividends for DANIBIO

Dividend Type Income
Dividend Frequency Annual
Last Dividend Net (on 2014-04-25) 12.8000
Dividend Yield (ttm) 3.67%

Performance for DANIBIO

1-Month +7.69% 1-Year +97.97%
3-Month +29.83% 3-Year +50.35%
Year To Date +29.83% 5-Year +30.48%
Expense Ratio 1.50

Top Fund Holdings for DANIBIO

Filing Date: 02/28/2015
Name Position Value % of Total
Pharmacyclics Inc 41,351 59,403,668 4.553%
Intercept Pharmaceuticals Inc 39,959 58,850,158 4.511%
Novavax Inc 883,892 53,806,477 4.124%
Celldex Therapeutics Inc 296,557 50,389,881 3.862%
Biogen Inc 17,055 46,474,564 3.562%
Seattle Genetics Inc 191,857 46,270,045 3.546%
Incyte Corp 80,961 46,241,341 3.544%
Charles River Laboratories Int 88,271 45,025,420 3.451%
United Therapeutics Corp 42,674 44,019,934 3.374%
Quintiles Transnational Holdin 101,010 43,667,501 3.347%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil